Skip to main content
SpringerLink
Log in

Nach Rezidiv oder Therapieresistenz

Panobinostat in der Zweitlinientherapie bei multiplem Myelom erfolgreich

  • neues aus der forschung
  • Published:
Info Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • San-Miguel JF et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195–206.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Barbara Kreutzkamp

Authors
  1. Barbara Kreutzkamp
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kreutzkamp, B. Panobinostat in der Zweitlinientherapie bei multiplem Myelom erfolgreich. Info Onkol. 18, 27 (2015). https://doi.org/10.1007/s15004-015-0770-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-015-0770-4

Search

Navigation